Raras
Buscar doenças, sintomas, genes...
Neoplasia endócrina múltipla
ORPHA:276161CID-10 · D44.8CID-11 · 2F7A.YDOENÇA RARA

Neoplasia endócrina múltipla (NEM) é um conjunto de condições de saúde raras, que são passadas de pais para filhos. Elas se caracterizam pelo aparecimento de dois ou mais tumores nas glândulas endócrinas e, às vezes, também podem surgir tumores em outros tecidos ou órgãos do corpo.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Neoplasia endócrina múltipla (NEM) é um conjunto de condições de saúde raras, que são passadas de pais para filhos. Elas se caracterizam pelo aparecimento de dois ou mais tumores nas glândulas endócrinas e, às vezes, também podem surgir tumores em outros tecidos ou órgãos do corpo.

Pesquisas ativas
10 ensaios
217 total registrados no ClinicalTrials.gov
Publicações científicas
6.422 artigos
Último publicado: 2026 May

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Europe
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D44.8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
30 sintomas
🫃
Digestivo
17 sintomas
🦴
Ossos e articulações
13 sintomas
🧠
Neurológico
10 sintomas
🫘
Rins
10 sintomas
🧬
Pele e cabelo
4 sintomas

+ 63 sintomas em outras categorias

Características mais comuns

Pectus excavatum
Mancha café com leite
Hipoglicemia
Adenoma sebáceo
Adenoma de células das ilhotas pancreáticas
Aumento da concentração circulante de prolactina
158sintomas
Sem dados (158)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 158 características clínicas mais associadas, ordenadas por frequência.

Pectus excavatum
Mancha café com leiteCafe-au-lait spot
HipoglicemiaHypoglycemia
Adenoma sebáceoAdenoma sebaceum
Adenoma de células das ilhotas pancreáticasPancreatic islet cell adenoma

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico6.422PubMed
Últimos 10 anos200publicações
Pico2025139 papers
Linha do tempo
2026Hoje · 2026🧪 1972Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

6 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Not applicable.

MEN1MeninDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionDeactivation of the beta-catenin transactivating complexFormation of the beta-catenin:TCF transactivating complexFormation of WDR5-containing histone-modifying complexes
MECANISMO DE DOENÇA

Familial multiple endocrine neoplasia type I

Autosomal dominant disorder characterized by tumors of the parathyroid glands, gastro-intestinal endocrine tissue, the anterior pituitary and other tissues. Cutaneous lesions and nervous-tissue tumors can exist. Prognosis in MEN1 patients is related to hormonal hypersecretion by tumors, such as hypergastrinemia causing severe peptic ulcer disease (Zollinger-Ellison syndrome, ZES), primary hyperparathyroidism, and acute forms of hyperinsulinemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
45.1 TPM
Tireoide
43.2 TPM
Cérebro - Hemisfério cerebelar
40.2 TPM
Fibroblastos
37.9 TPM
Baço
35.0 TPM
OUTRAS DOENÇAS (7)
multiple endocrine neoplasia type 1pituitary gigantismnull pituitary adenomaprolactin-producing pituitary gland adenoma
HGNC:7010UniProt:O00255
NTRK1High affinity nerve growth factor receptorCandidate gene tested inTolerante
FUNÇÃO

Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand (PubMed:1281417, PubMed:15488758, PubMed:17196528, PubMed:1849459, PubMed:1850821, PubMed:22649032, PubMed:27445338, PubMed:8325889). Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axon

LOCALIZAÇÃO

Cell membraneEarly endosome membraneLate endosome membraneRecycling endosome membrane

VIAS BIOLÓGICAS (1)
TRKA activation by NGF
MECANISMO DE DOENÇA

Congenital insensitivity to pain with anhidrosis

Characterized by a congenital insensitivity to pain, anhidrosis (absence of sweating), absence of reaction to noxious stimuli, self-mutilating behavior, and intellectual disability. This rare autosomal recessive disorder is also known as congenital sensory neuropathy with anhidrosis or hereditary sensory and autonomic neuropathy type IV or familial dysautonomia type II.

EXPRESSÃO TECIDUAL(Tecido-específico)
Próstata
5.7 TPM
Testículo
4.9 TPM
Cervix Endocervix
4.3 TPM
Útero
3.7 TPM
Fallopian Tube
3.5 TPM
OUTRAS DOENÇAS (4)
hereditary sensory and autonomic neuropathy type 4hereditary sensory and autonomic neuropathy type 5familial medullary thyroid carcinomadifferentiated thyroid carcinoma
HGNC:8031UniProt:P04629
ESR2Estrogen receptor betaCandidate gene tested inTolerante
FUNÇÃO

Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560) Lacks ligand binding ability and has no or only very low ERE binding activity resulting in the loss of ligand-dependent transactivation ability

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingPIP3 activates AKT signalingConstitutive Signaling by Aberrant PI3K in CancerExtra-nuclear estrogen signaling
MECANISMO DE DOENÇA

Ovarian dysgenesis 8

An autosomal dominant form of ovarian dysgenesis, a disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads.

EXPRESSÃO TECIDUAL(Baixa expressão)
Ovário
4.6 TPM
Testículo
3.9 TPM
Glândula adrenal
3.6 TPM
Linfócitos
2.3 TPM
Cervix Endocervix
1.4 TPM
OUTRAS DOENÇAS (2)
ovarian dysgenesis 8familial medullary thyroid carcinoma
HGNC:3468UniProt:Q92731
CDKN2BCyclin-dependent kinase 4 inhibitor BCandidate gene tested inTolerante
FUNÇÃO

Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (5)
Cyclin D associated events in G1Senescence-Associated Secretory Phenotype (SASP)Oncogene Induced SenescenceOxidative Stress Induced SenescenceSMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
OUTRAS DOENÇAS (2)
familial melanomamultiple endocrine neoplasia type 1
HGNC:1788UniProt:P42772
RETProto-oncogene tyrosine-protein kinase receptor RetDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, PubMed:28953886, PubMed:31118272). In contrast to most receptor tyrosine kinases, RET requires not onl

LOCALIZAÇÃO

Cell membraneEndosome membrane

VIAS BIOLÓGICAS (4)
RET signalingFormation of the ureteric budFormation of the nephric ductNPAS4 regulates expression of target genes
MECANISMO DE DOENÇA

Hirschsprung disease 1

A disorder of neural crest development characterized by absence of enteric ganglia along a variable length of the intestine. It is the most common cause of congenital intestinal obstruction. Early symptoms range from complete acute neonatal obstruction, characterized by vomiting, abdominal distention and failure to pass stool, to chronic constipation in the older child.

EXPRESSÃO TECIDUAL(Tecido-específico)
Substância negra
6.3 TPM
Pituitária
4.8 TPM
Cerebelo
4.0 TPM
Cólon sigmoide
4.0 TPM
Brain Frontal Cortex BA9
3.8 TPM
OUTRAS DOENÇAS (12)
multiple endocrine neoplasia type 2Bpheochromocytomafamilial medullary thyroid carcinomamultiple endocrine neoplasia type 2A
HGNC:9967UniProt:P07949
CDKN1BCyclin-dependent kinase inhibitor 1BDisease-causing germline mutation(s) inModerado
FUNÇÃO

Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA (PubMed:28666995). Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its ph

LOCALIZAÇÃO

NucleusCytoplasmEndosome

VIAS BIOLÓGICAS (10)
Cyclin D associated events in G1Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)SCF(Skp2)-mediated degradation of p27/p21TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle ArrestDNA Damage/Telomere Stress Induced Senescence
MECANISMO DE DOENÇA

Multiple endocrine neoplasia 4

Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2.

OUTRAS DOENÇAS (2)
multiple endocrine neoplasia type 4multiple endocrine neoplasia type 1
HGNC:1785UniProt:P46527

Variantes genéticas (ClinVar)

1,152 variantes patogênicas registradas no ClinVar.

🧬 MEN1: NM_001370259.2(MEN1):c.1186-1G>C ()
🧬 MEN1: NM_001370259.2(MEN1):c.767T>G (p.Leu256Arg) ()
🧬 MEN1: NM_001370259.2(MEN1):c.1009G>A (p.Ala337Thr) ()
🧬 MEN1: NM_001370259.2(MEN1):c.478dup (p.Ala160fs) ()
🧬 MEN1: NM_001370259.2(MEN1):c.361dup (p.Val121fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 6,680 variantes classificadas pelo ClinVar.

334
3006
3340
Patogênica (5.0%)
VUS (45.0%)
Benigna (50.0%)
VARIANTES MAIS SIGNIFICATIVAS
MEN1: NM_001370259.2(MEN1):c.1186-1G>C [Likely pathogenic]
MEN1: NM_001370259.2(MEN1):c.445+15G>C [Uncertain significance]
RET: NM_020975.6(RET):c.1685C>G (p.Thr562Ser) [Uncertain significance]
MEN1: NM_001370259.2(MEN1):c.1367G>C (p.Arg456Pro) [Uncertain significance]
RET: NM_020975.6(RET):c.574C>T (p.Pro192Ser) [Uncertain significance]

Vias biológicas (Reactome)

46 vias biológicas associadas aos genes desta condição.

Formation of the beta-catenin:TCF transactivating complex SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Deactivation of the beta-catenin transactivating complex Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) RHO GTPases activate IQGAPs Post-translational protein phosphorylation Formation of WDR5-containing histone-modifying complexes PLC-gamma1 signalling Signalling to RAS Frs2-mediated activation ARMS-mediated activation Retrograde neurotrophin signalling NGF-independant TRKA activation TRKA activation by NGF Signalling to p38 via RIT and RIN PI3K/AKT activation Signalling to STAT3 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ESR-mediated signaling Extra-nuclear estrogen signaling Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 RAF/MAP kinase cascade RET signaling NPAS4 regulates expression of target genes Formation of the nephric duct Formation of the ureteric bud SCF(Skp2)-mediated degradation of p27/p21 AKT phosphorylates targets in the cytosol DNA Damage/Telomere Stress Induced Senescence RHO GTPases activate CIT Constitutive Signaling by AKT1 E17K in Cancer TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Cyclin E associated events during G1/S transition p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates Cell Cycle FLT3 Signaling FOXO-mediated transcription of cell cycle genes Estrogen-dependent nuclear events downstream of ESR-membrane signaling Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 21
·Pré-clínico9
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 11 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Neoplasia endócrina múltipla

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

7 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

217 ensaios clínicos encontrados, 10 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
1.946 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.946

#1

Psychosocial Outcomes in Patients With Endocrine Tumor Syndromes: A Systematic Review.

Pediatric blood &amp; cancer2026 Mar

The combination of disease manifestations, the familial burden, and varying penetrance of endocrine tumor syndromes (ETSs) is unique. This review aimed to portray and summarize available data on psychosocial outcomes in patients with ETSs and explore gaps and opportunities for future research and care. Literature was systematically searched for articles on psychosocial outcomes in patients with multiple endocrine neoplasia (MEN), von Hippel-Lindau (VHL), and pathogenic variants (PVs) in succinate dehydrogenase (SDHx) genes via PubMed, PsychInfo, and Embase. Study quality was assessed using the CASP and STROBE appraisal tools. In total, 36 studies were found with fluctuating levels of evidence, of which five included pediatric patients. Overall, studies showed a considerable impact of ETSs on psychosocial outcomes such as quality of life (QoL), anxiety, and depression. Maladaptive coping, as well as social and financial restraints, were associated with poorer psychosocial outcomes. Surveillance protocols had ambivalent effects, both creating a sense of control and serving as a constant reminder of having an ETS. Parathyroid disease was associated with adverse psychosocial effects in MEN1. In MEN2A, gastrointestinal symptoms and having affected offspring were associated with poorer psychosocial outcomes. In MEN2B, pain was reported to interfere with daily life. Studies regarding VHL reported a wide range of experiences in patients and family members. Only a few studies were found for patients with PVs in SDHx genes, mainly describing effects due to the manifestation of disease or paraganglioma. Psychosocial outcomes and possible underlying factors seem different for each ETS. More research is needed to address psychosocial outcomes in children with an ETS.

#2

18F-Choline PET/CT Localization in a 20-Year Experience of Re-Operative Parathyroidectomy.

World journal of surgery2026 Mar 23

Reoperative parathyroidectomy is necessary in up to 10% of patients with persistent or recurrent primary hyperparathyroidism. Accurate preoperative localization is critical for surgical success and minimizing complications. Conventional imaging methods often yield inconclusive or false-negative results in this challenging patient population. To evaluate the diagnostic accuracy and clinical utility of 18F-fluorocholine positron emission tomography/computed tomography imaging compared to traditional imaging modalities of neck ultrasonography and 99mTechnetium-sestamibi parathyroid scintigraphy in patients undergoing reoperative parathyroidectomy. Retrospective cohort study of patients undergoing reoperative parathyroidectomy over a 20-year period (2005-2025). Localization imaging modalities, operative approaches, intraoperative parathyroid hormone monitoring, and surgical outcomes were analyzed. Single tertiary referral center specializing in endocrine surgery with a high-volume parathyroidectomy practice. 114 consecutive adult patients (aged ≥ 18 years) were included who underwent 124 reoperative parathyroidectomy operations for biochemically confirmed persistent or recurrent primary hyperparathyroidism. Patients were included if there was lithium-associated hyperparathyroidism or multiple endocrine neoplasia type 1 syndrome. Primary outcome included localization detection rates of imaging modalities performed. Secondary outcomes included type of surgical approach utilized, cause of failure from the primary operation, intraoperative parathyroid hormone monitoring response, biochemical cure rate, and surgical complications. 18F-fluorocholine positron emission tomography/computed tomography demonstrated a detection rate of 95.2%, outperforming 11C-methionine positron emission tomography/computed tomography (63.6%), fludeoxyglucose-positron emission tomography/computed tomography (50.0%), and neck ultrasonography (21.6%). In 90.5% of cases with negative or inconclusive conventional imaging, 18F-fluorocholine positron emission tomography/computed tomography accurately localized pathological parathyroid gland(s). A focused surgical approach (sternotomy or unilateral cervicotomy) was feasible in 87.1% of patients. Appropriate intraoperative parathyroid hormone monitoring decline was associated with a 95.8% biochemical cure rate. Complication rates were low, with vocal cord palsy in 0.8% and long-term hypoparathyroidism requiring calcium supplementation in 2.4%. 18F-fluorocholine positron emission tomography/computed tomography offers superior localization accuracy and a favorable radiation profile compared to conventional imaging options, supporting its use as a first-line modality in reoperative parathyroidectomy. Its application enables focused surgical interventions with high cure rates and low morbidity.

#3

How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach.

Annales d'endocrinologie2026 Mar 20

The discovery of RET as the primary driver of hereditary medullary thyroid cancer in multiple endocrine neoplasia syndrome drastically changed the diagnosis, management, and prognosis of patients with this rare endocrine tumor. First, from a diagnostic viewpoint, RET testing within families became possible, ruling out unnecessary follow-up for negative patients and proposing an adapted surveillance protocol for positive patients. Second, large-scale epidemiological studies paved the way for early "prophylactic" thyroidectomy, rendering a historically fatal disease curable. RET identification also allowed for proper screening of pheochromocytoma and primary hyperparathyroidism. Lastly, RET identification enabled the synthesis of new, highly effective, and well-tolerated specific inhibitors, which changed the outcome for patients with metastatic disease. The RET discovery is thus a perfect example of how gene discovery can transform the fate of a rare syndrome, and this is what will be described in this short review.

#4

Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).

World journal of surgery2026 Mar 20

To describe surgical indications, procedures and outcomes in patients operated for Zollinger-Ellison syndrome (ZES) in multiple endocrine neoplasia type 1 (MEN1) using a large nationwide cohort. Management of ZES in MEN1 remains controversial. All patients with ZES diagnosed through the MEN1 AFCE/GTE network from 1985 to 2015. Among 233 ZES patients, 66 (28%) were operated for ZES-related gastrinomas. Thirty-three (51%) procedures aimed to remove gastrinomas and associated pancreatic neuroendocrine tumors (pNET(s)) with appropriate resection. Thirty-two procedures (49%) aimed to remove gastrinomas alone (ZES group). Survival was decreased in patients metastatic at ZES diagnosis (p < 0.001). Fifteen-year survival among non-metastatic patients was not significantly better in operated patients (82% vs. 70%, p = 0.2). Perioperative mortality was nil. Metastatic lymph nodes were found in 30/42 lymphadenectomies (71%). The choice between pancreaticoduodenectomy versus duodenal focused surgery in the ZES group was associated with pre-operative detection of adenopathies (p > 0.001), leading to more frequent lymphadenectomies (p < 0.01). Previous pancreatic surgeries (30%) may have influenced the choice of ZES procedures. Gastrin levels were more frequently normalized when the duodenum and the head of pancreas were removed versus more localized duodenal surgeries (p < 0.01). The high rate of invaded nodes in lymphadenectomies in MEN1 patients operated for ZES, the absence of operative mortality, and the decreased survival in metastatic patients are indirect arguments for surgery. Pancreaticoduodenectomy may be indicated in young and fit individuals to better control hypergastrinemia and to prevent metastatic progression in the ZES group. Gastrinoma removal is justified when associated with large pNETs.

#5

Advanced disease and biochemical phenotype shift in multiple endocrine neoplasia type 2A-related pheochromocytoma.

JCEM case reports2026 Mar

The incidence of metastatic recurrence in multiple endocrine neoplasia type 2 (MEN2)-related pheochromocytoma is low, and reports are scarce. Moreover, there are no reports detailing changes in biochemical findings at the time of metastatic recurrence. We describe here the case of a woman in her 40s with MEN2-related pheochromocytoma. She exhibited an increase in spot urine normetanephrine levels 2 years and 8 months after laparoscopic right adrenalectomy for right pheochromocytoma, leading to the diagnosis of peritoneal dissemination and distant metastasis. She underwent chemotherapy, which was ineffective, and died 3 years and 2 months after the initial surgery. Metastasis and recurrence of MEN2-related pheochromocytoma are rare, and a change in the biochemical phenotype is also uncommon. Therefore, we report the clinical course of this case in detail.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.789 artigos no totalmostrando 198

2026

18F-Choline PET/CT Localization in a 20-Year Experience of Re-Operative Parathyroidectomy.

World journal of surgery
2026

How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach.

Annales d'endocrinologie
2026

Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).

World journal of surgery
2026

RET Lys666Asn has a low rate of MEN2-related tumors but may be associated with pheochromocytoma.

Hormones (Athens, Greece)
2026

Advanced disease and biochemical phenotype shift in multiple endocrine neoplasia type 2A-related pheochromocytoma.

JCEM case reports
2026

[Multiple endocrine neoplasia syndrome type 1: analysis of data from 102 patients from 43 families in the population of the Russian Federation].

Problemy endokrinologii
2026

Challenges and unmet needs of [18F]fluorocholine PET in hyperparathyroidism: A framework for refining current practice and advancing parathyroid imaging.

European journal of nuclear medicine and molecular imaging
2026

Systematic structure-based analysis of RET variants in MEN2A, Hirschsprung's disease, and their paradoxical co-occurrence.

Disease models &amp; mechanisms
2026

Bilateral pheochromocytoma: case series and review of treatment strategies based on genetic mutations.

Translational andrology and urology
2026

In-depth Genetic and Molecular Characterization of Unilateral Coexisting Adrenal Cortical Adenoma and Carcinoma in the Context of MEN1 Syndrome.

Endocrine pathology
2026

Health-Related Quality of Life in Children with Multiple Endocrine Neoplasia (MEN) and their Siblings.

The Journal of clinical endocrinology and metabolism
2026

Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist Administration for Prostate Cancer.

IJU case reports
2026

Multiple endocrine neoplasia with an atypical clinical course and a MEN1 gene variant of uncertain pathogenicity: A case report.

Medicine
2026

Corrigendum to: "Health-related quality of life of Multiple Endocrine Neoplasia type 1 patients: A mixed methods systematic review" [Eur J Cancer, Vol. 227, 9 September 2025, 115671].

European journal of cancer (Oxford, England : 1990)
2026

Primary Hyperparathyroidism in the Pediatric Population: Surgical Considerations and Outcomes: A Narrative Review.

Diagnostics (Basel, Switzerland)
2026

Redefining Pituitary Neuroendocrine Tumors in MEN1: Prevalence, Clinical Behavior, and Implications for Long-Term Surveillance.

Current oncology (Toronto, Ont.)
2026

Multiple endocrine neoplasia type 1 with MEN1 c.652C>T (p.Arg218Trp): variant reclassified to likely pathogenic.

JCEM case reports
2026

Two novel multiple endocrine neoplasia type 1 variants caused thymic neuroendocrine tumor: a case report.

Hereditary cancer in clinical practice
2026

Rare cases in two Chinese MEN2A families with RET C634Y germline mutation-a homozygous female patient and heterozygous identical twins: a systematic review of literature.

Frontiers in endocrinology
2026

Ventricular fibrillation triggered by recurrent hypoglycemia in a patient with insulinoma associated with MEN1: case report and review of literature.

Endocrine journal
2026

Incretin Mimetics in Cancer and Cardiovascular Disease: JACC: CardioOncology State-of-the-Art Review.

JACC. CardioOncology
2025

Rank-based learning: a novel high-throughput algorithm resilient to missing data and effective for datasets with small sample size.

Briefings in bioinformatics
2026

Rare RET Variants in a Patient With MEN2A and Multiple Follicular-Derived Thyroid Tumors: A Case Report and Review of the Literature.

International journal of surgical pathology
2026

Cancer predisposition syndromes: an imaging review.

Cancer imaging : the official publication of the International Cancer Imaging Society
2026

Thyroid collision tumor and Graves' disease: A case report and review of literature.

World journal of clinical cases
2026

RET germline mutations drive tumorigenesis but not tumor aggressiveness in MEN 2.

Endocrine
2026

Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers.

The Journal of clinical endocrinology and metabolism
2026

Multiple endocrine neoplasia type 5: emerging evidence and clinical perspectives.

Endocrine-related cancer
2026

Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.

Insights into imaging
2026

Case Report: Investigation and characterization of a multiple endocrine neoplasia type 1 case and its pedigree.

Frontiers in endocrinology
2026

Distinct epigenetic aging in sporadic and hereditary neuroendocrine neoplasms.

Clinical epigenetics
2026

Lipid synthesis seems to drive proliferation in Men1 mouse adrenals and human adrenocortical cell lines.

Endocrine-related cancer
2026

Surgical and Oncologic Outcomes After Pancreatectomy for Pancreatic Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 and von Hippel-Lindau Syndrome: A Large, Multi-Institutional, Cohort Study.

Journal of the American College of Surgeons
2026

Insulin Resistance Among Patients With Multiple Endocrine Neoplasia Type 1: A Systemic Review and Meta-Analysis.

AACE endocrinology and diabetes
2026

A Concurrent Finding of Pulmonary Sarcoidosis, Primary Hyperparathyroidism, Thyroid Nodules, and Adrenal Tumor in a Sexagenarian.

Cureus
2026

Persistent Hypercalcemia: Diagnostic Complexity With Multiglandular Hyperparathyroidism, Renal Cell Carcinoma, and Hereditary Tumor Features.

Cureus
2026

Efficacy and safety of pralsetinib in multiple endocrine neoplasia type 2-associated pheochromocytoma: a case report.

Therapeutic advances in endocrinology and metabolism
2026

Atypical presentation and association of medullary thyroid carcinoma: reports from a tertiary care center in Northwest India.

Endocrinology, diabetes &amp; metabolism case reports
2026

Clinical Approach to Medullary Thyroid Carcinoma in Pregnancy: Experience and Review of the Literature.

JCEM case reports
2026

Metformin suppresses MEN1-associated pancreatic and pituitary neuroendocrine tumors: evidence from mouse models and clinical data.

Endocrine-related cancer
2025

Utility of in Vivo Corneal Confocal Microscopy in Atypical MEN2B Findings. A Case Report.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti
2026

Blood-Based Immunoglobulin-Bound Neoantigen Signatures Associated with Multiple Endocrine Neoplasia Type 1-Related Duodenopancreatic Neuroendocrine Tumor Progression.

Journal of the American College of Surgeons
2025

A Rare Case of Coexisting Medullary and Papillary Thyroid Carcinomas With Parathyroid Adenoma in Pancreatic Neuroendocrine Tumour (pNET).

Cureus
2025

Cardiac Tamponade As the Initial Presentation of a Thymic Neuroendocrine Tumour: A Case Report.

CJC open
2025

Multiple Endocrine Neoplasia Type 1 Presenting as Recurrent Overt Gastrointestinal Bleeding and Ulceration: A Diagnostic Challenge.

Cureus
2026

[Endocrinology : what's new in 2025].

Revue medicale suisse
2026

Histological evidence of familial GH-PitNET associated with germline MAX mutation.

European journal of endocrinology
2026

Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A.

Endocrine-related cancer
2026

Radiological Surveillance for Pituitary Adenomas in Multiple Endocrine Neoplasia Type 1: A Longitudinal Cohort Study.

The Journal of clinical endocrinology and metabolism
2026

Psychosocial Outcomes in Patients With Endocrine Tumor Syndromes: A Systematic Review.

Pediatric blood &amp; cancer
2025

Late-Onset Gastrointestinal Manifestations of Multiple Endocrine Neoplasia Type 2B (MEN2B): Diffuse Ganglioneuromatosis Causing Megacolon.

Cureus
2026

Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping.

Virchows Archiv : an international journal of pathology
2025

Ultrasound and Scintigraphy for Preoperative Localization in Primary Hyperparathyroidism: A Single-Center Experience.

Cureus
2025

Multiple Endocrine Neoplasia Type 5 due to Germline MAX Mutations: A Systematic Review of Tumor Spectrum and Clinical Features.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.

Genes
2025

Non-Syndromic Ganglioneuromatosis of the Gallbladder, an Extremely Rare Condition: Case Report and Literature Review.

Reports (MDPI)
2026

Multiple endocrine neoplasia type 1 syndrome due to novel Alu insertion.

Cancer genetics
2026

Redefining the prevalence of different clinical variants in MEN2A and their correlation with RET germline mutations: a single-center series and experience.

Endocrine-related cancer
2025

Characteristics and outcomes of cubital tunnel decompression in diabetic patients receiving glucagon-like peptide-1 receptor agonists.

Clinics in shoulder and elbow
2026

[Integration of Molecular, Genetic, and Surgical Evidence Into the Indication Criteria for Preventive Thyroid Surgery].

Zentralblatt fur Chirurgie
2025

From misclassified AIP variant to carney complex: a case report and retrospective evaluation of PRKAR1A in pituitary tumor predisposition.

Pituitary
2025

New directions in MEN1 management: navigating the new clinical practice guidelines.

European journal of endocrinology
2024

[Ganglioneuroma of the Small Intestine Mimicking Crohn's Disease].

Acta gastroenterologica Latinoamericana
2025

[The 514th case: urinary stone excretion, elevated blood glucose, pancreatic mass,and co-secretion of multiple hormones].

Zhonghua nei ke za zhi
2026

Delay in Diagnosis of Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: Clinical and Endocrinological Profiles from a Retrospective Cohort Study.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2025

Case Report: Novel likely pathogenic MEN1 mosaic mutation in the family with MEN-1 syndrome.

Frontiers in endocrinology
2025

Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies.

Endocrine oncology (Bristol, England)
2025

Presentation of multiple endocrine neoplasia type 2A-associated ectopic cushing's syndrome: case report and a systematic review.

Frontiers in endocrinology
2025

Colonic Ganglioneuroma-A Rare Finding During Colonoscopy.

Diagnostics (Basel, Switzerland)
2025

The clinical challenge of MEN1 phenocopies: insights from a multicentric national retrospective study.

Journal of endocrinological investigation
2026

Role of MEN1 mutations on postoperative outcomes of patients with multiple endocrine neoplasia type 1-related primary hyperparathyroidism: a single center experience.

Journal of endocrinological investigation
2025

Loss of heterozygosity and absence of MAX immunostaining in a prolactinoma associated with multiple endocrine neoplasia type 5 (MEN5).

Pituitary
2025

Population-Based Evidence of Familial Clustering in Pulmonary Carcinoid Tumors: Insights From the Utah Population Database.

Cureus
2025

Phenotypic characterization of a new case of multiple endocrine neoplasia type 4 associated with de novo germline and somatic CDKN1B pathogenic variants.

Annales d'endocrinologie
2025

A Case of Pediatric Pancreatic Insulinoma Diagnosed 4 Years after the Onset.

Surgical case reports
2025

Perioperative Care of a Patient With Carney Complex.

Cardiology research
2026

Dermatologic Features of Endocrine Tumor Syndromes-Systematic Review and Meta-Analysis.

International journal of dermatology
2025

Unusual Dual Brain Tumor Morphologies in an MEN1 Patient: A Case Report of Diagnostic Challenges and Methylation Insights.

International journal of molecular sciences
2025

Bilateral and recurrent adrenocortical carcinoma in MEN1: a case report and review of the literature.

Endocrine oncology (Bristol, England)
2025

Untying the Next Genetic Thread in a Family With MEN2A Syndrome: A Case Report.

Clinical case reports
2025

Laparoscopy-assisted total colectomy for progressive megacolon due to intestinal ganglioneuromatosis in a young adult with multiple endocrine neoplasia type 2B: a case report.

International journal of surgery case reports
2025

A 14-yr-old boy with a pathogenic MEN1 variant was diagnosed with asymptomatic insulinoma during routine follow-up.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2024

CLINICAL EVALUATION, DIAGNOSIS AND TREATMENT OF PHEOCHROMOCYTOMA.

Acta clinica Croatica
2026

Medullary thyroid carcinoma exclusively associated with a homozygous RET V778I pathogenic variant: a case report with review of literature.

Endocrine journal
2025

Advances in the clinical management of parathyroid disorders: report from the 2024 workshop by the ESE educational program on parathyroid disorders.

European journal of endocrinology
2025

MEN1-Related Neuroendocrine Tumors Show c-MET Overexpression.

Journal of the Endocrine Society
2025

Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.

Nuklearmedizin. Nuclear medicine
2025

Targeting menin in lysine methyltransferase 2A/nucleophosmin-mutated leukemia: A novel strategy from epigenetic dysregulation to clinical therapy (Review).

Oncology letters
2025

68Ga-DOTA-TATE PET/CT improves accuracy and guides management in multiple endocrine neoplasia type 1 (MEN-1) patients with suspected duodeno-pancreatic neuroendocrine tumours.

Endocrine oncology (Bristol, England)
2025

Pheochromocytoma manifested as a surgical emergency.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2025

Genotype-phenotype correlations of germline mutations in exon 10 of the RET proto-oncogene from 14 MEN2A families of Ethnic Han Chinese.

PloS one
2026

Risk Factors for Pituitary Adenoma Development in Multiple Endocrine Neoplasia Type 1: A Nationwide Study of 240 Cases.

The Journal of clinical endocrinology and metabolism
2025

Familial Carney complex with embolic ischemic stroke: a case report and literature review.

Frontiers in oncology
2025

Do Prognostic Differences Exist Among High-Risk RET Mutations? A Comparison of Outcomes Between the RET C634R and Other C634 Mutations in Hereditary Medullary Thyroid Carcinoma.

Thyroid : official journal of the American Thyroid Association
2025

Extent of Surgical Resection and Predictors of Outcomes in MEN1-related Hyperparathyroidism: A Systematic Review and Meta-analysis.

The Journal of clinical endocrinology and metabolism
2025

Multi-molecular imaging showing tumour heterogeneity and differing diagnostic performance in a case with metastatic pheochromocytoma.

EJNMMI reports
2025

Approach to the Patient With Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1.

The Journal of clinical endocrinology and metabolism
2025

Gastrointestinal surveillance in patients with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome.

Scandinavian journal of gastroenterology
2025

Giant Pheochromocytoma With Non-classical Symptoms: A Case Report to Expand Clinical Awareness.

Cureus
2025

Multifocality and bilaterality in medullary thyroid cancer: basis for a proof-of-concept safety of lobectomy.

European thyroid journal
2025

Health-related quality of life of Multiple Endocrine Neoplasia Type 1 patients: A mixed methods systematic review.

European journal of cancer (Oxford, England : 1990)
2025

Familial MEN1 Syndrome with Atypical Renal Features and a Coexisting CLDN16 Variant: A Case Series.

Journal of clinical medicine
2025

Medullary thyroid cancer arising from a thyroid rest: a case report.

Journal of surgical case reports
2025

Thyroid Storm in the Shadows of Multiple Endocrine Neoplasia (Men) 2A: A Case of Overlapping Endocrine Emergencies.

European journal of case reports in internal medicine
2025

A Case of Micro-medullary Thyroid Carcinoma Presenting as Cancer of Unknown Primary.

Cureus
2025

Integrated 18F-FCH PET/4D-CT in a Case of Supernumerary Parathyroid Glandular Hyperplasia With Incidentally Detected Thymic NET.

Clinical nuclear medicine
2025

A Comparative Study on the Multidimensional Features of Hereditary and Sporadic Medullary Thyroid Carcinoma Patients: A Single-Center Retrospective Study.

Medicina (Kaunas, Lithuania)
2025

Inhibitory Effects of Vandetanib on Catecholamine Synthesis in Rat Pheochromocytoma PC12 Cells.

International journal of molecular sciences
2025

Geospatial inheritance across the breath of the RET mutational landscape of multiple endocrine neoplasia 2A.

Endocrine
2025

When Diarrhea Tells a Deeper Story: A Curious Case of Metastatic Medullary Thyroid Carcinoma.

Cureus
2025

Multiple endocrine neoplasia type 1 with neuroglycopenic symptoms with a novel heterozygous MEN1 gene mutation.

World journal of surgical oncology
2025

A Long-Term Follow-Up of 2 Cases of Subclinical Acromegaly.

AACE endocrinology and diabetes
2025

RET Y791F in MEN2: a variant presumed non-pathogenic, yet lacking conclusive evidence of insignificance.

Gland surgery
2025

Novel germline likely pathogenic frameshift variant of the MEN1 gene contributes to multiple endocrine neoplasia type 1: a case report with review of literature.

Endocrine journal
2025

Primary Hyperparathyroidism: A Case Series, Patient-Centered Approach to Diagnosis and Management Review.

Annali italiani di chirurgia
2025

Laryngeal Multiple Mucosal Neuromas: A Diagnostic Challenge.

Journal of voice : official journal of the Voice Foundation
2025

RET (C620R) Mutation in a Hirschsprung Disease Family: A Case Report Unveiling Asymptomatic Pheochromocytoma and Unmanifested Medullary Thyroid Carcinoma.

Cureus
2025

The role of thymectomy during parathyroidectomy in multiple endocrine neoplasia type 1-associated hyperparathyroidism: a systematic review and meta-analysis.

World journal of surgical oncology
2025

ASO Author Reflections: Patient Selection and Technique for Robotic Spleen-Preserving Distal Pancreatectomy.

Annals of surgical oncology
2025

Cyclic Cushing syndrome associated with cadherin-23 and multiple endocrine neoplasia type 1 gene mutations accompanied by bilateral primary papillary thyroid carcinoma.

Polish archives of internal medicine
2025

A Case of Advanced Renal Cell Carcinoma With Concomitant Development of Multiple Endocrine Neoplasia Type 1 That Affected Treatment Progress With Immunotherapy.

IJU case reports
2025

Epidemiology and clinical outcomes of clinically suspected multiple endocrine neoplasia type 1 in South Korea: a nationwide cohort study.

Frontiers in endocrinology
2025

Neuroendocrine neoplasms as a lynch syndrome manifestation: a case report and comprehensive literature review.

Frontiers in endocrinology
2025

From prominent corneal nerves to multiple endocrine neoplasia type 2B.

The lancet. Diabetes &amp; endocrinology
2025

68 Ga-DOTATATE PET/CT-Guided Surgical Resection for Complete Remission of Multifocal Insulinomas in a Father and Son With MEN1 Syndrome.

Clinical nuclear medicine
2026

Circulating Gene Expression Assay as a Diagnostic and Prognostic Biomarker for Pancreatic Neuroendocrine Tumors in MEN1.

The Journal of clinical endocrinology and metabolism
2025

Contribution of Germline Predisposition to Pediatric Thyroid Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research
2025

Medullary Thyroid Cancer Risk and Mortality in Carriers of Incidentally Identified MEN2A RET Variants.

JAMA network open
2025

Updated Recommendations for Pediatric Surveillance in Hereditary Endocrine Neoplasia Syndromes: Multiple Endocrine Neoplasias, Hyperparathyroidism-Jaw Tumor Syndrome, and Carney Complex.

Clinical cancer research : an official journal of the American Association for Cancer Research
2025

Pituitary incidentaloma: a Pituitary Society international consensus guideline statement.

Nature reviews. Endocrinology
2025

Four decades of the RET gene: From discovery to tumor-agnostic therapy.

Journal of the Formosan Medical Association = Taiwan yi zhi
2025

Robotic Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.

Annals of surgical oncology
2025

Sporadic Coexistence of Parathyroid Adenoma, Papillary Thyroid Carcinoma, Pheochromocytoma, and Cardiac Myxoma: A Multidisciplinary Approach to an Extremely Rare Tumor Constellation.

Cureus
2025

Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice.

The lancet. Diabetes &amp; endocrinology
2025

Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis.

The lancet. Diabetes &amp; endocrinology
2025

68 Ga-Exendin-4 PET/CT Enables Identification of Multiple and Ectopic Insulinoma in a Patient With Multiple Endocrine Neoplasia 1.

Clinical nuclear medicine
2025

Serums miR-24-3p and miR-1301-3p as Potential Biomarkers in MEN1 Syndrome.

International journal of molecular sciences
2025

Last decade of advances in gastric neuroendocrine tumors: Innovations, challenges, and future directions.

World journal of clinical oncology
2025

Importance of understanding a diagnostic-treatment algorithm for primary hyperparathyroidism-induced acute pancreatitis during pregnancy.

World journal of gastroenterology
2026

Pancreatic Neuroendocrine Tumor Leading to a Diagnosis of Multiple Endocrine Neoplasia Type 1.

DEN open
2025

Multiple endocrine neoplasia type 2A: a diagnostic challenge case report.

Annals of medicine and surgery (2012)
2025

Double mutation for multiple endocrine neoplasia associated with congenital adrenal hyperplasia.

Endocrinology, diabetes &amp; metabolism case reports
2025

Successful treatment of metachronous insulinoma in a patient with multiple endocrine neoplasia type 1 syndrome.

Polish archives of internal medicine
2025

Partial adrenalectomy for pheochromocytoma in the multiple endocrine neoplasia type 2 population: Time to reconsider?

Surgery
2025

Chromogranin a and pancreatic polypeptide are not suitable for the screening of pancreatic neuroendocrine tumors in MEN1 - a long-term follow-up study.

Endocrine
2025

A Pituitary Macroadenoma Cosecreting Prolactin and Growth Hormone in a Patient With Multiple Endocrine Neoplasia Type 4.

JCEM case reports
2025

A neural substrate of comorbid depressive symptoms in alcohol use.

Molecular psychiatry
2025

Case Report: A novel likely pathogenetic variant of the MEN1 gene in multiple endocrine neoplasia type 1.

Frontiers in endocrinology
2025

Bilateral Pheochromocytoma with a Novel Pathogenic Variant in the MAX gene: A Case Report.

Journal of the ASEAN Federation of Endocrine Societies
2025

[Clinical polymorphism of primary hyperparathyroidism in children].

Problemy endokrinologii
2025

Recurrence of malignant insulinoma in the context of multiple endocrine neoplasia type 1: a case report.

Journal of surgical case reports
2025

Safety and Efficacy of Peptide Receptor Radionuclide Therapy in Multiple Endocrine Neoplasia Syndrome: A Single-center Experience.

Clinical nuclear medicine
2025

Clinical phenotypes and genetic screening in hereditary primary hyperparathyroidism: A single-center case series.

Annales d'endocrinologie
2025

Beyond Hypertension: Hypoglycemia as an Atypical Presentation of Pheochromocytoma in Neurofibromatosis Type 1.

Cureus
2025

An Updated Perspective of the Clinical Features and Parathyroidectomy Impact in Primary Hyperparathyroidism Amid Multiple Endocrine Neoplasia Type 1 (MEN1): Focus on Bone Health.

Journal of clinical medicine
2025

Multimodal Imaging Approach to MEN-1 Syndrome-Associated Tumors.

Diagnostics (Basel, Switzerland)
2025

Multicentric B-cell lymphoma, phaeochromocytoma and amyloid-rich thyroid carcinoma in a common warthog (Phacochoerus africanus): a case of multiple endocrine neoplasia type 2?

Journal of comparative pathology
2025

Benefit of splenectomy in distal pancreatectomy for neuroendocrine tumours: multicentre retrospective study.

BJS open
2025

Oncocytic subtype of well differentiated neuroendocrine tumor: clinicopathologic and molecular associations of a cohort diagnosed on fine needle aspiration (FNA).

Journal of the American Society of Cytopathology
2025

MEN2: surgical precision in the era of precision medicine.

Endocrine-related cancer
2025

Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations.

JCO oncology advances
2025

Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
2024

A Case Series Study of Solitary Mucosal Neuroma-Rare Cases of Benign Peripheral Neurogenic Tumours.

Clinical pathology (Thousand Oaks, Ventura County, Calif.)
2025

Kinome profiling reveals pathogenic variant specific protein signalling networks in MEN2 children with Medullary Thyroid Cancer.

NPJ precision oncology
2025

Robotic Approach to Surgery for Pheochromocytoma in Children: A Case Series.

Journal of endourology
2025

Predictors of Mortality in Patients With Multiple Endocrine Neoplasia Type 1.

Clinical endocrinology
2025

An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2.

Diseases (Basel, Switzerland)
2025

Heterozygous Men1(+/T) Knockout Mice Do Not Develop Bronchopulmonary Neuroendocrine Hyperplasia or Neoplasia but Bronchial Adenocarcinoma.

Advances in respiratory medicine
2025

Highlights from the AACE Consensus Statement on Multiple Endocrine Neoplasia Type 1: A Patient's Perspective.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

Importance of early detection in multiple endocrine neoplasia type 1: Clinical insights and future directions.

World journal of gastrointestinal oncology
2025

American Association of Clinical Endocrinology Consensus Statement on Management of Multiple Endocrine Neoplasia Type 1.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2024

Forearm Auto-Transplantation of Adenomatous Parathyroid Tissue to Prevent Post-Surgical Hypoparathyroidism: A Case Report.

West African journal of medicine
2025

Population Prevalence of the Major Thyroid Cancer-Associated Syndromes.

The Journal of clinical endocrinology and metabolism
2025

Insulinoma: A Novel Presentation of Multiple Endocrine Neoplasia 4.

AACE clinical case reports
2025

A Novel Mutation in a Family With Multiple Endocrine Neoplasia Type 1 and Aggressive Pancreatic Neuroendocrine Tumors.

AACE clinical case reports
2025

Significance of ectopic intrathyroidal thymic tissue detected on ultrasound in different paediatric age groups: a proposed classification to guide investigation and management.

European journal of pediatrics
2025

Primary Hyperparathyroidism: Clinical, Biochemical, and Radio-Pathological Profiles of 804 Patients - A Retrospective Study from South India.

Indian journal of endocrinology and metabolism
2025

p.M918W, a novel RET germline variant: a case report and literature review of the possible association of multiple endocrine neoplasia type 2B and Charcot-Marie-Tooth disease.

Endocrine journal
2025

Prognostic value of clinical parameters and exosomal lncRNA NEAT1_1 in MEN1-related non-functioning pancreatic neuroendocrine tumors.

Journal of neuroendocrinology
2025

Primary hyperparathyroidism during pregnancy: ultrasound as an accurate preoperative localization imaging modality.

Orphanet journal of rare diseases
2025

Management and Long-Term Monitoring of a Young Patient with Pheochromocytoma and RET Mutation: A Case Report.

International medical case reports journal
2025

[Microwave ablation for primary hyperparathyroidism related to multiple endocrine neoplasia type 1 in 3 cases of a family].

Zhonghua nei ke za zhi
2025

Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis.

Seminars in cancer biology
2025

Bone Mineral Density Changes in Multiple Endocrine Neoplasia Type 1: A Systematic Review and Meta-Analysis of Prevalence and Parathyroidectomy Outcomes.

The archives of bone and joint surgery
2025

Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss.

Biomolecules
2025

Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome Clinical Presentation and the Role of Newer Functional Imaging in the Diagnosis and Management: A Case Report.

Cureus
2025

Genomic testing for RET in the clinic: UK and global perspective.

Endocrine-related cancer
2025

Multiple endocrine neoplasia type 1 in childhood and description of a novel variant.

Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo
2025

Prevalence and genetics of "de novo" MEN2 syndromes.

The Journal of clinical endocrinology and metabolism
2025

Pure mucosal neuroma syndrome, not MEN2B.

BMJ case reports
2025

A Five-Year Journey to Diagnosis: Resolving Persistent Hypoglycemia Through Successful Insulinoma Resection-A Case Report.

Clinical case reports
2025

Challenging Perioperative Management of a MEN2A Syndrome Patient Complicated by Eisenmenger Syndrome.

Turkish journal of anaesthesiology and reanimation
2025

A Novel Multiple Endocrine Neoplasia Type 1 Gene Variant Found in Scalp Pulmonary Neuroendocrine Tumor Metastasis.

JCEM case reports
2025

Post-surgical natural history of MEN2A with RET C634R mutation and bilateral cervical node metastasis: a case report.

Annals of medicine and surgery (2012)
2025

Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.

The Journal of clinical endocrinology and metabolism
2025

Long-Term Follow-Up in Medullary Thyroid Carcinoma Patients.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Primary Hyperparathyroidism in MEN2 Syndromes.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
2025

Pheochromocytoma in MEN2.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Ver todos os 2.789 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Neoplasia endócrina múltipla.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Neoplasia endócrina múltipla

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Psychosocial Outcomes in Patients With Endocrine Tumor Syndromes: A Systematic Review.
    Pediatric blood &amp; cancer· 2026· PMID 41491677mais citado
  2. 18F-Choline PET/CT Localization in a 20-Year Experience of Re-Operative Parathyroidectomy.
    World journal of surgery· 2026· PMID 41873061mais citado
  3. How has genetics changed the diagnosis and care of multiple endocrine neoplasia type 2? The merits and pitfalls of a genetic-based diagnostic and therapeutic approach.
    Annales d'endocrinologie· 2026· PMID 41866073mais citado
  4. Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'&#xe9;tude des Tumeurs Endocrines).
    World journal of surgery· 2026· PMID 41862416mais citado
  5. Advanced disease and biochemical phenotype shift in multiple endocrine neoplasia type 2A-related pheochromocytoma.
    JCEM case reports· 2026· PMID 41837230mais citado
  6. Associations of selected atypical non-neuroendocrine cancers with multiple endocrine neoplasia type 1.
    J Endocr Soc· 2026· PMID 41994491recente
  7. Extracellular signalling regulates gastrin transcription through site-specific phosphorylation and nuclear redistribution of Menin.
    bioRxiv· 2026· PMID 41993411recente
  8. Gastric neuroendocrine tumors: a comprehensive analysis of clinicopathological characteristics and survival outcomes from a reference center.
    Arq Bras Cir Dig· 2026· PMID 41983868recente
  9. Genetics of Familial Acromegaly and Pituitary Gigantism.
    J Clin Endocrinol Metab· 2026· PMID 41965096recente
  10. The clinical consequences of diagnostic delay in sporadic pediatric MEN2B: a case series of 6 children.
    Eur J Pediatr· 2026· PMID 41961175recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:276161(Orphanet)
  2. MONDO:0017169(MONDO)
  3. GARD:21044(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q1553018(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Neoplasia endócrina múltipla
Compêndio · Raras BR

Neoplasia endócrina múltipla

ORPHA:276161 · MONDO:0017169
Prevalência
Unknown
Herança
Autosomal dominant, Not applicable
CID-10
D44.8 · Neoplasia de comportamento incerto ou desconhecido com comprometimento pluriglandular
CID-11
Ensaios
10 ativos
Início
All ages
Prevalência
0.0 (Europe)
MedGen
UMLS
C0027662
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades